View Item 

Show simple item record

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics

dc.contributor.authorPescovitz, M. D.en_US
dc.contributor.authorConti, D.en_US
dc.contributor.authorDunn, J.en_US
dc.contributor.authorGonwa, T.en_US
dc.contributor.authorHalloran, Philen_US
dc.contributor.authorSollinger, H. W.en_US
dc.contributor.authorTomlanovich, S.en_US
dc.contributor.authorWeinstein, S.en_US
dc.contributor.authorInokuchi, S.en_US
dc.contributor.authorKiberd, B.en_US
dc.contributor.authorKittur, D.en_US
dc.contributor.authorMerion, Robert M.en_US
dc.contributor.authorNorman, D.en_US
dc.contributor.authorShoker, A.en_US
dc.contributor.authorWilburn, R.en_US
dc.contributor.authorNicholls, Ajen_US
dc.contributor.authorArterburn, S.en_US
dc.contributor.authorDumont, E.en_US
dc.date.accessioned2010-06-01T19:06:14Z
dc.date.available2010-06-01T19:06:14Z
dc.date.issued2000-06en_US
dc.identifier.citationPescovitz, Md; Conti, D; Dunn, J; Gonwa, T; Halloran, P; Sollinger, H; Tomlanovich, S; Weinstein, S; Inokuchi, S; Kiberd, B; Kittur, D; Merion, Rm; Norman, D; Shoker, A; Wilburn, R; Nicholls, Aj; Arterburn, S; Dumont 1 , E (2000). "Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics." Clinical Transplantation 14(3): 179-188. <http://hdl.handle.net/2027.42/72291>en_US
dc.identifier.issn0902-0063en_US
dc.identifier.issn1399-0012en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72291
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10831074&dopt=citationen_US
dc.format.extent329630 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMunksgaard International Publishersen_US
dc.publisherBlackwell Publishing Ltden_US
dc.rightsMunksgaard 2000en_US
dc.subject.otherIntravenous (I.V.)en_US
dc.subject.otherKidney Transplantationen_US
dc.subject.otherMycophenolate Mofetilen_US
dc.subject.otherPharmacokineticsen_US
dc.subject.otherSafetyen_US
dc.titleIntravenous mycophenolate mofetil: safety, tolerability, and pharmacokineticsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, Ann Arbor, MI, USA;en_US
dc.contributor.affiliationotherIndiana University Hospital, Indianapolis, IN;en_US
dc.contributor.affiliationotherAlbany Medical College, New York, NY, USA;en_US
dc.contributor.affiliationotherUniversity of California at San Diego Medical Center, CA, USA;en_US
dc.contributor.affiliationotherBaylor University Medical Center, Dallas, TX, USA;en_US
dc.contributor.affiliationotherUniversity of Alberta, Edmonton, Canada;en_US
dc.contributor.affiliationotherUniversity of Wisconsin, Madison, WI, USA;en_US
dc.contributor.affiliationotherUniversity of California, San Francisco, CA, USA;en_US
dc.contributor.affiliationotherTampa General Hospital, FL, USA;en_US
dc.contributor.affiliationotherCalifornia Pacific Medical Center, San Francisco, CA, USA;en_US
dc.contributor.affiliationotherVictoria Transplant Program, Halifax, Nova Scotia, Canada;en_US
dc.contributor.affiliationotherJohns Hopkins Hospital, Baltimore, MD, USA;en_US
dc.contributor.affiliationotherOregon Health Sciences University, Portland, OR, USA;en_US
dc.contributor.affiliationotherRoyal University Hospital, Saskatoon, Saskatchewan, Canada;en_US
dc.contributor.affiliationotherVirginia Mason Medical Center, Seattle, WA, USA;en_US
dc.contributor.affiliationotherRoche Pharmaceuticals, Palo Alto, CA, USAen_US
dc.identifier.pmid10831074en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72291/1/j.1399-0012.2000.140301.x.pdf
dc.identifier.doi10.1034/j.1399-0012.2000.140301.xen_US
dc.identifier.sourceClinical Transplantationen_US
dc.identifier.citedreference 1  Sollinger HW, for The US Renal Transplant Mycophenolate Mofetil Study Group Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.en_US
dc.identifier.citedreference 2  The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61 ( 7 ): 1029.en_US
dc.identifier.citedreferenceKobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998: 66: 507.en_US
dc.identifier.citedreference 4  Mathew TH, for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998: 65: 1450.en_US
dc.identifier.citedreferenceLee WA, Gu L, Miksztal AR et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990: 7 ( 2 ): 161.en_US
dc.identifier.citedreferenceEugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transpl Proc 1991: 23 ( 2 ): 15.en_US
dc.identifier.citedreferenceKimball J, Pescovitz MD, Book BK et al. Mycophenolate mofetil reduces human IgG anti-ATGAM antibody formation. Transplantation 1995: 60: 1379.en_US
dc.identifier.citedreferenceSmith KGC, Isbel NM, Catton MG et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transpl 1998: 13: 160.en_US
dc.identifier.citedreferenceBullingham R, Monroe S, Nicholls A et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in health subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996: 36 ( 4 ): 315.en_US
dc.identifier.citedreferenceBullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharm 1998: 34 ( 6 ): 429.en_US
dc.identifier.citedreferenceNicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 1998: 31 ( 5 ): 329.en_US
dc.identifier.citedreferenceShaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration–clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem 1998: 44 ( 2 ): 381.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1399-0012.2000.140301.x.pdf
Size:
321.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.